Determinants of expression of SARS-CoV-2 entry-related genes in upper and lower airways

To the Editor,

The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To better understand COVID-19 the genetic and environmental factors on susceptibility and severity, detailed knowledge of regulation of genes required for viral entry into respiratory epithelial cells is needed.

We assessed the gene expression of SARS-CoV-2 receptors and activating proteases, and their regulation by smoking, inhaled-corticosteroids (ICS), genetics/epigenetics using nasal and bronchial samples from nine independent cohorts (see extended methods, Table S1).

SARS-CoV-2 cell entry factor (SCEF) genes have higher expression levels in nose than bronchi in matched samples across two cohorts (Figure 1A–D, Table S2), mirroring results from previous smaller studies. Smoking was associated with higher expression of ACE2, TMPRSS2, FURIN, and BSG in bronchial brushes, supporting a recent meta-analysis, but not in nasal brushes (Figure 1E,F). In contrast, smoking was associated with lower expression of CTSL in nasal and bronchial brushings (Table S3). The impact of smoking on the expression of ACE2 and BSG gene expression differs significantly between these tissues (Table S4). None of these genes were associated with sex or age. Cell-type deconvolution of RNA-seq data revealed that all SCEF genes strongly correlated with predicted secretory cell proportions across tissues (Figure 1G–I), in particular ACE2 (Figure 1J), in line with recent scRNA-seq data. We observed higher proportions of secretory cells (goblet & club cells) in bronchial samples from current smokers compared to ex/never-smokers, which was not observed in nasal brushes (Figure 1K), which may explain the lack of increase of ACE2 expression in nasal samples. We next performed a cross-sectional analysis for nasal samples in four adult cohorts (NORM/OLIVA (n = 76), CRUKPAP (n = 405), U-BIOPRED (n = 89), and INCI (n = 79)); and one pediatric cohort: PIAMA (n = 228), and one adult cohort: INDURAIN (n = 167). We identified 143 eQTMs for the different SCEF genes (Figure 2J, Table S12). The nasal eQTMs were influenced by age and sex, but not smoking (Table S13), whereas bronchial eQTMs for TMPRSS2 were associated with smoking and age (Table S14). ACE2 expression in bronchial biopsies was associated with 6 CpG sites, two of which were in the promoter region of the adjacent TMEM27 gene. ACE2 and TMEM27 expression was correlated (Figure 2K.L) and both associated with methylation of cg20473453 (Figure 2M), indicating possible co-regulation of ACE2 and TMEM27.

In conclusion, although SCEF genes are more highly expressed in upper airways, first and secondhand smoke exposure only appears to influence the expression of these genes in the lower airways. CpG methylation, but not genetic variation, was associated with expression of several SCEF genes in bronchus and nose, which was associated with age, gender, and smoking. Finally, ICS decreases expression of ACE2 in bronchial biopsies. Together, these results indicate that the enhanced SCEF expression in the lower airways due to cigarette smoke exposure and the reduced expression in subjects taking ICS may underlie the increased susceptibility to COVID-19 in smokers and the clinical efficacy of ICS.

Shared first author: Hananeh Allee, Florian Massip, Cancan Qi, Maria Stella de Biase, Jos van Nijffnatten, Elin T.G. Kersten, Nazanin Z. Kermani, Basil Khuder.

FIGURE 1  Expression genes required for SARS-CoV-2 entry into cells in nasal and bronchial brushes and relationship with goblets cells. Heatmaps and plots of SARS-CoV-2 cell entry related in matched nasal and bronchial brushes from the NORM (n = 77) (A & C) and CRUKPAP (n = 162) cohorts (B & D). Plots comparing ACE2, TMPRSS2, CTSL, BSG, FURIN, and NRP1 expression in current and ex/never-smokers in nasal and bronchial brushes, (E) NORM and (F) CRUKPAP. Plots comparing ACE2 expression in ex-smokers and duration of smoke cessation in nasal and bronchial brushes. (G) UMAP of merged bronchial biopsy and nasal brush single cell datasets. (H) Heatmap of selected genes associated with each epithelial cell type. (I) Correlation heatmap of cellular deconvolution cell proportions compared to SARS-CoV-2 cell entry related (Spearman’s rho correlation was conducted). (J) Association of cellular deconvolution of Goblet cells with ACE2 expression. (K) Goblet/secretory cell fraction separated based on tissue type and smoking status. Cellular deconvolution was performed using AutoGeneS. Statistics for deconvolution results were conducted using Mann-Whitney test, while the correlation heatmap was analyzed using Spearman correlation. *p < 0.05, ***p value < 0.001 Abbreviations: MI, microarray intensity; VST, variance-stabilizing transformation. Statistics for deconvolution results were conducted using Mann-Whitney test for unpaired and Wilcoxon for paired.
Figure 2  Transcriptional response of SARS-CoV-2 cell entry related genes to clinical characteristics, methylation, and environmental stimuli. Expression of (A) ACE2, (B) TMPRSS2, (C) CTSL, (D) BSG, (E) NRP1, and (F) FURIN in bronchial biopsies; INDURAIN (n = 207), U-BIOPRED (n = 108) and GLUCOLD (n = 56) and bronchial brushes CRUKPAP dataset (n = 228) and NORM/TIP (n = 167), separated based on smoking status. The effect of acute smoke exposure on (G) ACE2 in bronchial brushings 24 h after smoking and not smoking 3 cigarettes. (H) The influence of secondhand smoke in children of SARS-CoV-2 cell entry in bronchial biopsies. The influence of 6 month ICS and Placebo compared to baseline from bronchial biopsies of COPD patients, (I) ACE2. Top eQTM for (J) ACE2. (K) Correlation of ACE2 and TMEM27 (Spearman's (rho) correlation was conducted). (L) Diagram of the top CpG site associated with ACE2 expression. (M) EQTM for TMEM27 and the top CpG site associated with ACE2 expression. Statistics was done using an unpaired t-test. *p < 0.05 Abbreviations: MI, microarray intensity VST, variance-stabilizing transformation.
**FUNDING INFORMATION**

Chan Zuckerberg Initiative; European Union’s H2020 Research and Innovation Program, Grant/Award Number: 874656; Innovative Medicines Initiative Joint, Grant/Award Number: 115010; European Union’s Seventh Framework Programme, Grant/Award Number: FP7/2007-2013; Longfonds Junior Fellowship; Helmholtz Association, Grant/Award Number: NIH K08HL146943; Parker B. Francis Fellowship; ATS Foundation/Boehringer Ingelheim Pharmaceuticals Inc. Research Fellowship; Cancer Research UK Cambridge Centre; Cambridge NIHR Biomedical Research Centre; Cambridge Bioresource; The Netherlands Organization for Health Research and Development; The Netherlands Organization for Scientific Research; The Netherlands Lung Foundation, Grant/Award Number: AF 4.1.14.001; The Netherlands Ministry of Spatial Planning, Housing, and the Environment; The Netherlands Ministry of Health, Welfare, and Sport; China Scholarship Council

**CONFLICT OF INTEREST**

The authors declare that there are no competing interest in relation to this work.
REFERENCES


SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

ORCID

Cancan Qi https://orcid.org/0000-0003-3825-5802
Xiaoyu Zhang https://orcid.org/0000-0002-6033-0525
Paul A. Reyfman https://orcid.org/0000-0002-6435-6001